Cancer immunotherapy can yield lasting responses, yet numerous tumors stay hard for immune cells to access, detect, and eliminate. A fresh review explores how bioactive nanomaterials may overcome these obstacles using three interconnected approaches. Surface-adaptive nanomaterials shift their properties as they travel from the bloodstream into tumors, antigen-engineering platforms make weakly immunogenic cancer cells more noticeable, and tumor microenvironment-modulating systems diminish signals that curb immune activity. By linking transport, immune detection, and local reprogramming, the structure provides design guidelines for nanomedicines that could boost antitumor responses, enhance treatment accuracy, and restrict unnecessary immune activation in healthy tissues across various tumor types.
Immune checkpoint inhibitors, cancer vaccines, and cellular therapies have transformed oncology, but most patients still fail to gain sustained benefits. Solid tumors build layered defenses: abnormal blood vessels and dense tissue hinder drug access, unstable antigen expression reduces immune recognition, and suppressive cells, cytokines, and metabolic conditions exhaust tumor-fighting lymphocytes. Systemic stimulation can also trigger immune-related side effects, creating a tough balance between effectiveness and safety. Nanomaterials offer adjustable size, surface chemistry, and cargo capacity, yet systems designed around only one barrier may fall short elsewhere in the treatment process. Given these hurdles, deeper investigation is required into integrated nanomaterials that coordinate tumor delivery, antigen presentation, and immune microenvironment reprogramming.
Researchers from Nankai University published (DOI: 10.1007/s10118-026-3567-z) the review online on April 24, 2026, in Chinese Journal of Polymer Science. The work outlines three complementary nanomaterial strategies aimed at overcoming physiological barriers, boosting tumor immunogenicity, and easing immune suppression, offering a unified structure for creating more precise and effective bioactive nanomaterials for cancer immunotherapy and clarifying how these methods might be combined.
The first approach focuses on surface-adaptive nanomaterials (SANs), which stay fairly stable during circulation but react to acidity or hypoxia inside tumors. These changes can reveal adhesive surfaces, improve tumor retention, or trigger controlled release of immune-regulating cargo. The second approach employs antigen engineering to restore immune visibility. Some nanoplatforms attach immunogenic signals to tumor-cell membranes, helping natural killer (NK) cells or tumor-associated macrophages detect malignant cells. Others induce endoplasmic reticulum stress or lysosomal disruption, prompting cancer cells to display immunogenic signals and release damage-associated molecular patterns (DAMPs). Additional systems capture tumor-associated antigens (TAAs) and deliver them to antigen-presenting cells (APCs), especially dendritic cells (DCs), to support major histocompatibility complex class I (MHC-I) presentation and T-cell activation. The third approach reshapes the tumor microenvironment (TME) by concentrating checkpoint inhibitors within tumors, removing suppressive proteins, or regulating immune-related pathways at the gene level. Studies highlighted in the review reported stronger tumor control, reduced metastasis, or improved immune activation in mouse models. Across these cases, the authors argue that circulation stability, tumor-selective activation, antigen presentation, and immune reprogramming should be designed as linked functions rather than separate technical goals.
The authors stated that bioactive nanomaterials ought to be seen not merely as passive carriers, but as responsive systems that engage with shifting biological conditions. A clinically viable platform must stay controlled in the bloodstream, activate selectively within tumors, strengthen immune recognition, and reduce local suppression, they said. The authors added that progress will rely on clearer understanding of nano-bio interactions, stronger immune-safety testing, predictable biodistribution, durable immune memory, and manufacturing methods capable of delivering reproducible materials at clinical scale, rather than just dramatic tumor shrinkage in small animal studies.
The framework could support nanomedicines customized to a patient’s tumor antigens, immune status, and microenvironment. Future platforms may combine programmable materials with engineered cells, ribonucleic acid (RNA) circuits, gene-editing tools, radiotherapy, chemotherapy, or targeted inhibitors to broaden therapeutic windows and overcome resistance. Translation will require standardized assessment of cytokine release, complement activation, off-target immune stimulation, pharmacokinetics, clearance, and long-term protection against tumor recurrence. Good manufacturing practice (GMP)-compatible production and quality control (QC) will also be essential for batch consistency, stability, sterility, and scalability. Building these requirements into early design could help move promising preclinical systems toward clinical testing for immunotherapy-resistant cancers.
References
DOI
10.1007/s10118-026-3567-z
Original Source URL
https://doi.org/10.1007/s10118-026-3567-z
Funding Information
This study was financially supported by the National Natural Science Foundation of China (Nos. 52525310, 52373143, 22077073 and 52203172).
Lucy Wang
BioDesign Research
email us here
